http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006076655-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_307e287ea9caf317280ad3afb66f73b2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7d7c62b03c517dde10665f7fabfa9a7 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 |
filingDate | 2006-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78120ffff7599540e851d0eb39b13835 |
publicationDate | 2006-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2006076655-A2 |
titleOfInvention | Use of alpha-2 adrenergic receptor agonists |
abstract | The present invention provides a strategy to compensate for deficiency in the alpha-2C receptor by administering an agonist of different receptors, the alpha-2A and/or dopamine d2 receptors. These receptors are fully functional and receptive to stimulation by an agonist. Agonism of the alpha-2A and/or dopamine d2 receptors by clonidine, Nolomirole or other suitable agonist may down regulate epinephrine production, and hence compensate for the deficiency in the alpha-2C receptor. Such methods are useful for treating a variety of cardiovascular disorders. |
priorityDate | 2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 247.